3,501 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by Arizona State Retirement System

Arizona State Retirement System acquired a new position in GeneDx Holdings Corp. (NASDAQ:WGS) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,501 shares of the company’s stock, valued at approximately $269,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Barclays PLC increased its holdings in shares of GeneDx by 346.3% in the 3rd quarter. Barclays PLC now owns 18,921 shares of the company’s stock valued at $803,000 after purchasing an additional 14,681 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in GeneDx during the third quarter worth about $325,000. Charles Schwab Investment Management Inc. increased its holdings in GeneDx by 304.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after buying an additional 110,666 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of GeneDx during the 3rd quarter valued at approximately $301,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of GeneDx during the 3rd quarter worth approximately $604,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

Insider Transactions at GeneDx

In related news, CEO Katherine Stueland sold 10,501 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $76.75, for a total value of $805,951.75. Following the completion of the transaction, the chief executive officer now directly owns 71,146 shares in the company, valued at approximately $5,460,455.50. This represents a 12.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 922 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $94.72, for a total value of $87,331.84. Following the transaction, the chief financial officer now owns 5,446 shares in the company, valued at $515,845.12. This trade represents a 14.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 126,176 shares of company stock worth $11,295,519 over the last ninety days. 27.30% of the stock is currently owned by corporate insiders.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $98.47 on Friday. GeneDx Holdings Corp. has a one year low of $7.72 and a one year high of $115.60. The stock has a market cap of $2.76 billion, a PE ratio of -50.24 and a beta of 1.90. The business’s fifty day moving average price is $84.60 and its two-hundred day moving average price is $69.67. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The firm had revenue of $95.64 million during the quarter, compared to analysts’ expectations of $82.24 million. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. On average, analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the subject of several research analyst reports. TD Cowen raised their price objective on GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, GeneDx currently has a consensus rating of “Moderate Buy” and a consensus price target of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.